Make that 2 ap­proved RNAi drugs at Al­ny­lam af­ter the FDA of­fers a speedy OK on ul­tra-rare dis­ease drug

Sev­en­teen years in­to the game, Al­ny­lam’s piv­ot in­to com­mer­cial op­er­a­tions is pick­ing up speed.

The bell­wether biotech $AL­NY has nabbed their sec­ond FDA OK for an RNAi drug, this time for givosir­an, the on­ly ther­a­py now ap­proved for acute he­pat­ic por­phyr­ia. This sec­ond ap­proval came months ahead of the Feb­ru­ary dead­line — even af­ter win­ning pri­or­i­ty re­view fol­low­ing their ‘break­through’ ti­tle ear­li­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.